Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Jan 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how long it takes for tests to show that Chlamydia and Gonorrhea are no longer present in patients after they have received treatment for these infections. Specifically, the researchers want to find out how quickly patients clear the infections from their bodies after being treated with standard medicines. The trial is currently looking for participants, and anyone between the ages of 18 and older who has had a simple case of either Chlamydia or Gonorrhea may be eligible to join.

To participate, individuals must be receiving care at a specific hospital department and have been treated with the recommended medications for their infections. Participants will be asked to provide informed consent, meaning they understand the purpose of the study and any potential risks involved. Throughout the trial, participants can expect to undergo tests to monitor the clearance of the infections after treatment. It's important to note that individuals with more complicated infections or certain health conditions may not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Patients attending the Trait d'Union department at the Nouvel Hôpital Civil for PrEP consultations, AES or HIV infection.
• • Over 18 years of age
• • Male or female
• • Who have had an uncomplicated CT and/or NG infection treated with currently recommended therapies (Ceftriaxone 500mg DU for NG infections, Doxycycline 200mg per day for 1 week for rectal CT infections and Azithromycin 1g DU or Doxycycline 7 days for other CT infections).
• • Subject affiliated to a social health insurance scheme
• • Subject able to understand the aims and risks of the research and to give dated and signed informed consent
• Exclusion Criteria:
• • - Complicated CT and/or NG infections: epididymitis, prostatitis, upper genital infection, extra-genital involvement (keratoconjunctivitis, arthritis, skin involvement, Fiessinger-Leroy-reiter syndrome, Fitz-Hugh-Curtis syndrome).
• • Interfering treatments and associated diseases: Severe immunosuppression (HIV infection with CD4 less than 200/mm3, chemotherapy in the last 6 months, active haemopathy, congenital immune deficiency, immunosuppressive treatment including corticosteroid therapy for more than 4 weeks or organ transplant.
• • Impossibility of giving the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.).
• • Subject under court protection
• • Subject under guardianship or curatorship